Mitomycin C and Vinblastine in Advanced Refractory Breast Cancer

A combination of mitomycin C and vinblastine was administered as salvage treatment in 44 patients with heavily pretreated refractory breast cancer. Response rate was 23% (10 of 44) including one complete response of lung metastases. The highest response rate was seen in intrathoracic localizations (45 %). Median duration of response was 6.5 months (range, 3–17). Treatment was generally well tolerated, and only 25 % of patients developed nausea and vomiting. Neurologic toxicity was represented by paresthesia (8 patients) and constipation (one patient). Mild leukopenia was observed in 30 of 172 treatment cycles, but it exceeded grade 2 in only 5 patients. Considering the good compliance of this regimen and the poor prognosis of patients with advanced refractory disease, the combination of mitomycin C plus vinblastine appears to be useful as salvage treatment for metastatic breast cancer.

[1]  J. Verweij,et al.  Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. , 1987, European journal of cancer & clinical oncology.

[2]  D. Hayes,et al.  New agents and new medical treatments for advanced breast cancer. , 1987, Seminars in oncology.

[3]  M. Tattersall,et al.  Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. , 1987, Cancer treatment reports.

[4]  L. Lenaz,et al.  Mitomycin C in advanced breast cancer. , 1985, Cancer treatment reviews.

[5]  G. Hortobagyi.  Mitomycin-C in breast cancer. , 1985, Seminars in oncology.

[6]  R. K. Knight,et al.  Mitomycin C and vinblastine in the treatment of advanced breast cancer. , 1985, European journal of cancer & clinical oncology.

[7]  G. Hortobagyi,et al.  Five‐day continuous‐infusion vinblastine in the treatment of breast cancer , 1985, Cancer.

[8]  B. Issell,et al.  Mitomycin: ten years after approval for marketing. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Hortobagyi,et al.  A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma , 1985, Cancer.

[10]  T. Miller,et al.  Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Bonadonna,et al.  Chemotherapy of breast cancer: current views and results. , 1983, International journal of radiation oncology, biology, physics.

[12]  D. V. Van Echo,et al.  Mitomycin C and vinblastine chemotherapy for advanced breast cancer , 1981, Cancer.

[13]  C. Vogel,et al.  Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. , 1978, Cancer treatment reports.

[14]  G. Hortobagyi,et al.  Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy , 1978, Cancer.

[15]  J. Lhéritier,et al.  Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation. , 1974, Biomedicine / [publiee pour l'A.A.I.C.I.G.].